Predictors of clinical events in patients with Fabry disease: the role of chronic kidney disease


Cite item

Full Text

Abstract

Fabry disease is a rare disorder characterized by high frequency of severe organ manifestations in young patients. Aim. To determine predictors of clinical events in patients with Fabry disease. Materials and methods. We recruited 100 adult (over 18 years) patients with Fabry disease that was confirmed by enzymatic and genetic studies. The main outcome was a composite of end - stage renal disease, cardiac (arrhythmia and cardioverter/pacemaker implantation) and cerebrovascular (transient ischemic attack, stroke) events. Kaplan-Meier analysis was performed for event - free survival. Cox regression model was used to examine the risk of composite endpoint. Results and disscussion. Forty - seven of the 100 patients (38 males and 9 females) experienced clinical events. The median age of the first event was 39 [32; 49] years. In Kaplan-Meier analysis, the age of the first event was significantly lower among men than women, (p<0.0001), patients with decreased glomerular filtration rate (eGFR) at the time of first detected kidney involvement (p=0.002) and patients with proteinuria (p<0.0001). Using Cox regression analysis, eGFR<60 ml/min/1.73 m2 (HR 3.79, 95% CI 1.87-7.66, p<0.0001), high proteinuria (HR 1.29, 95% CI 1.04-1.59, p=0.022) and increased left ventricular myocardial mass index (LVMMI, HR 1.01, 95% CI 1.002-1.02, p=0.015) were associated with greater risk of developing a composite event after adjustment for gender and age. Eleven males were died. All deceased patients had end - stage renal disease. High proteinuria (HR 1.57, 95% CI 1.05-2.35, p=0.029) and increased LVMMI (HR 1.006, 95% CI 1-1.012, p=0.038) were predictors of death after adjustment for gender, but lost its effect on event occurrence after adjustment for hemodialysis duration. The type of mutation in the GLA gene was not a predictor of clinical events. Conclusion. Chronic kidney disease was an important risk factor of clinical events. Increased LVMMI and high proteinuria were both predictors of death and composite event. Estimated GFR lower than 60 ml/min/1.73m2 at the time of first detected kidney involvement was also associated with greater risk of developing a composite event.

About the authors

S. V Moiseev

Sechenov First Moscow State Medical University (Sechenov University); Lomonosov Moscow State University

Email: clinpharm@mtu-net.ru
зав. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Moscow, Russia

E. A Karovaikina

Sechenov First Moscow State Medical University (Sechenov University)

м.н.с. НИО Здоровьесберегающих технологий НТПБ ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Moscow, Russia

N. M Bulanov

Sechenov First Moscow State Medical University (Sechenov University); Lomonosov Moscow State University

с.н.с. НИО Здоровьесберегающих технологий НТПБ ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова», ассистент каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Moscow, Russia

A. S Moiseev

Lomonosov Moscow State University

ординатор каф. внутренних болезней факультета фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова» Moscow, Russia

V. V Fomin

Sechenov First Moscow State Medical University (Sechenov University)

проректор ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Moscow, Russia

References

  1. Zarate Y.A, Hopkin R.J. Fabry’s disease. Lancet. 2008;372(9647):1427-35. doi: 10.1016/S0140-6736(08)61589-5
  2. Eng C.M, Fletcher J, Wilcox W.R, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30(2):184-92. doi: 10.1007/s10545-007-0521-2
  3. Мухин Н.А., Моисеев В.С., Моисеев С.В. и др. Диагностика и лечение болезни Фабри. Клиническая фармакология и терапия. 2013;22(2):11-20.
  4. Mac Dermot K.D, Holmes A, Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750-60. doi: 10.1136/jmg.38.11.750
  5. Schiffmann R, Warnock D.G, Banikazemi M, et al. Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102-11. doi: 10.1093/ndt/gfp031
  6. Каровайкина Е.А., Моисеев С.В., Буланов Н.М. и др. Распространенность и основные проявления поражения почек у пациентов с болезнью Фабри. Клиническая фармакология и терапия. 2018;27(4):46-52.
  7. Smid B.E, van der Tol L, Cecchi F, et al. Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol. 2014;177(2):400-8. doi: 10.1016/j.ijcard.2014.09.001
  8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Intern Suppl. 2012;3(1):1-150.
  9. Нефрология. Клинические рекомендации. Под ред. Е.М. Шилова, А.В. Смирнова, Н.Л. Козловской. М.: ГЭОТАР-Медиа, 2016. 808 c.
  10. Моисеев С.В., Намазова-Баранова Л.С., Савостьянов К.В. и др. Распространенность и клинические проявления болезни Фабри у диализных пациентов. Клиническая фармакология и терапия. 2017;26(2):27-33.
  11. Patel V, O’Mahony C, Hughes D, et al. Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease. Heart. 2015;101(12):961-6. doi: 10.1136/heartjnl-2014-306782
  12. Ortiz A, Cianciaruso B, Cizmarik M, et al. End - stage renal disease in patients with Fabry disease: Natural history data from the Fabry Registry. Nephrol Dial Transplant. 2009;25(3):769-75. doi: 10.1093/ndt/gfp554
  13. Wanner C, Oliveria J.P, Ortiz A, et al. Prognostic indicators of renal disease progression in adults with fabry disease: Natural history data from the Fabry Registry. Clin J Am Soc Nephrol. 2010;5(12):2220-8. doi: 10.2215/CJN.04340510
  14. Rob D, Marek J, Dostálová G, et al. Uric acid as a marker of mortality and morbidity in fabry disease. PLoS One. 2016;11(11):e0166290. doi: 10.1371/journal.pone.0166290
  15. Siegenthaler M, Huynh-Do U, Krayenbuehl P, et al. Impact of cardio - renal syndrome on adverse outcomes in patients with Fabry disease in a long - term follow - up. Int J Cardiol. 2017;249:261-7. doi: 10.1016/j.ijcard.2017.09.027
  16. Talbot A.S, Lewis N.T, Nicholls K.M. Cardiovascular outcomes in fabry disease are linked to severity of chronic kidney disease. Heart. 2015;101(4):287-93. doi: 10.1136/heartjnl-2014-306278

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies